Patents Examined by Trevor Love
  • Patent number: 10660827
    Abstract: The present invention relates to a cosmetic composition, comprising: an oil phase in an amount of 20% by weight or more, preferably from 28% to 45% by weight, relative to the total weight of the composition, said oil phase including preferably at least one non-volatile oil, a pulverulent phase in an amount of 40% by weight or more, preferably from 55% to 70% by weight, relative to the total weight of the composition, at least one hydrophobic film-forming polymer, the cosmetic composition is obtainable, and preferably obtained, by a process comprising the steps of: mixing said oil phase, said hydrophobic film-forming polymer(s), said pulverulent phase, and at least one additional solvent to prepare a slurry; and shaping said slurry in a container by compression and/or aspiration to prepare the cosmetic composition.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: May 26, 2020
    Assignee: L'OREAL
    Inventors: Masako Shirai, Caroline Lebre-Lemonnier, Padraig MacDermott, Hiroyo Kameyama, Kana Nakayama
  • Patent number: 10653776
    Abstract: Drug delivery formulations, uses thereof and methods of making same are provided in order to reduce the potential for abuse, misuse or improper administration of an addictive substance or any active substance and to prevent, reduce, inhibit, or delay purposeful or accidental overdose of an active substance by ingesting too many dosage forms at once, for example.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: May 19, 2020
    Assignee: Intellipharmaceutics Corp.
    Inventor: Isa Odidi
  • Patent number: 10646440
    Abstract: The present invention discloses a sanguisorbigenin polymer micelle, and it is prepared by following raw/auxiliary materials at predetermined weight ratio: 30 parts of sanguisorbigenin and 100-5000 parts of mPEG-PLA-Phe(Boc). Quality evaluation test indicates that only using mPEG-PLA-Phe(Boc) according to the present invention as carrier materials, the quality of sanguisorbigenin polymer micelle prepared is the best, and using other materials can lead to the lowered preparation quality. In pharmacodynamic experiment, compared with the model group, the sanguisorbigenin micelle of the present invention can significantly increase the amounts of WBC, RBC, PLT, NEUT, and HGB in peripheral blood, and the efficacy is obviously better than the original drug of sanguisorbigenin, indicating the sanguisorbigenin polymer micelle has a better treatment and/or prevention effects on bone marrow suppression, and can improve the bioavailability of insoluble drug of sanguisorbigenin.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: May 12, 2020
    Assignee: SICHUAN INLU WEITE PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventor: Shilin Yang
  • Patent number: 10632147
    Abstract: The present invention provides methods for treating conditions that involve infection and/or inflammation, including acute and chronic inflammation, as well as delayed-type and immediate-type hypersensitivity. The invention in various embodiments provides methods for treating microbial infection and the associated inflammatory response, as well methods for treating inflammatory conditions that spawn or are susceptible to secondary microbial infection. Further, the invention provides methods for treating inflammation, such as chronic inflammation, without any associated microbial infection.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: April 28, 2020
    Assignee: URGO US, INC.
    Inventors: Claire Sampson, Mark Sampson, Svetlana Panicheva, Cary Schockemoehl
  • Patent number: 10624338
    Abstract: The present invention relates to microencapsulation technology and specifically, nitrite salt microencapsulation and uses of microencapsulated nitrite in the manufacture of animal pest baits, especially baits to be used in humane methods for controlling feral pig and possum populations.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: April 21, 2020
    Inventors: Linton Staples, Duncan MacMorran
  • Patent number: 10617699
    Abstract: The present invention relates to an orally administrable pharmaceutical dosage form for use in the prevention and/or treatment of a cardiovascular disease which includes (a) acetylsalicylic acid as a first active agent and (b) HMG-CoA reductase inhibitor as a second active agent. The HMG-CoA reductase inhibitor is selected from atorvastatin and rosuvastatin and salts thereof. The present invention is formulated in (a) two or more single separate coated dosage units in which the coating includes one or more water-soluble polymer and no more than 0 to 5% by weight of the coating of water-insoluble or enteric polymer, and in which the dosage units include 8 to 12 mg/cm2 coating and show an immediate release profile; and (b) one or more single separate coated dosage units.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: April 14, 2020
    Assignees: FERRER INTERNACIONAL, S.A., FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III
    Inventors: Pablo Martin Sanz, Javier Urbano Hurtado
  • Patent number: 10617716
    Abstract: The present invention in various aspects and embodiments provides methods and formulations for treating inflammatory conditions of the skin and/or conditions involving compromised skin barrier function. Such diseases include blistering diseases of the skin, hereditary defects in skin barrier function, hyperproliferative conditions involving the skin, conditions associated with aging or damaged skin, immunological disorders involving the skin, among others.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: April 14, 2020
    Assignee: URGO US, INC.
    Inventors: Mark Sampson, Svetlana Panicheva, Cary Schockemoehl
  • Patent number: 10617791
    Abstract: Provided is a hydrogel. The hydrogel includes a liquid and a plurality of microfibers suspended in the liquid as an entangled network. The entangled network includes physically entangled microfibers that are mechanically interlocked.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: April 14, 2020
    Assignees: THE TRUSTEES OF PRINCETON UNIVERSITY, UNIVERSITÀ DI NAPOLI “FEDERICO II” DIPARTIMENTO DI INGEGNERIA CHIMICA, DEI MATERIALI E DELLA PRODUZIONE INDUSTRIALE
    Inventors: Janine K. Nunes, Antonio Perazzo, Stefano Guido, Howard A. Stone
  • Patent number: 10617633
    Abstract: Disclosed is a topical skin care formulation comprising water, kaolin, glycerin, lactobacillus ferment, Helianthus annuus seed extract, and Terminalia ferdinandiana fruit extract.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: April 14, 2020
    Assignee: Mary Kay Inc.
    Inventors: David Gan, Patricia Jacoby
  • Patent number: 10592168
    Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: March 17, 2020
    Assignee: INDIVIOR UK LIMITED
    Inventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
  • Patent number: 10588858
    Abstract: The present invention teaches a foamable pharmaceutical and cosmetic compositions comprising an aprotic polar solvent; foam compositions and uses thereof.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: March 17, 2020
    Assignee: FOAMIX PHARMACEUTICALS LTD.
    Inventors: Dov Tamarkin, David Schuz, Tal Berman, Yohan Hazot
  • Patent number: 10583095
    Abstract: Carotenoid compositions are described for management, treatment, and/or prevention of stress by reducing cortisol levels and/or improving distribution and/or density of macular pigment and thus improving overall health status. More particularly, a subject in need thereof for the method has disturbed macular pigment optical density or increased levels of cortisol as markers of psychological and physiological stress. Methods are also described of administering macular carotenoid compositions in daily doses of at least or about 0.005 mg/kg body weight of lutein, and at least or about 0.001 mg/kg body weight of meso-zeaxanthin and zeaxanthin isomer along with at least one food grade excipient and evaluating overall health status. The composition may be derived from plant extract containing xanthophylls and/or xanthophylls esters. The composition also reduces cortisol levels in the blood and relieves physiological stress, thus improving overall health status of a subject in need thereof.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: March 10, 2020
    Assignee: OmniActive Health Technologies Limited
    Inventors: Jayant Deshpande, James M. Stringham, Vijaya Juturu
  • Patent number: 10568323
    Abstract: A treatment device for a beehive includes a strip having at least one layer. The at least one layer is formed from a biodegradable material permeable to water, such as paper. At least one layer is saturated with a treatment fluid. A reinforcement or join is provided to or adjacent each longitudinal edge of the strip, to protect and/or reinforce the longitudinal edges to mechanically resist attack by bees in the hive.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: February 25, 2020
    Assignee: P J Staples Limited
    Inventor: Phillip John Haycock
  • Patent number: 10556965
    Abstract: This document provides methods and materials related to treating cancer. For example, methods and materials for using particles (e.g., nanoparticles) containing (a) one or more molecules having the ability to bind to a cancer cell (e.g., a human breast cancer cell) and (b) one or more molecules having the ability to bind to an APC (e.g., a human macrophage) to treat cancer are provided.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: February 11, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Yon Son Betty Kim, Robert E. Wharen, Jr., Hengfeng Yuan, Wen Jiang
  • Patent number: 10558394
    Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: February 11, 2020
    Assignee: INDIVIOR UK LIMITED
    Inventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
  • Patent number: 10537104
    Abstract: The present invention relates to pesticidal mixtures. In particular it relates to mixtures of loline alkaloids with other pesticides. Such mixtures are useful for the control of insect pests and for improving the yield of crop plants.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: January 21, 2020
    Assignee: Syngenta Participations AG
    Inventor: Patrik Hoegger
  • Patent number: 10531684
    Abstract: Provided is a powder containing ferric pyrophosphate that affords high iron absorbability, as a main component of an oral iron preparation. The present invention relates to a composite powder containing ferric pyrophosphate, which is a powder containing ferric pyrophosphate and a sodium component, wherein (1) the content of ferric pyrophosphate is 95 wt % or higher, and (2) a (Fe+Na)/P molar ratio is 0.8 to 1.0.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: January 14, 2020
    Assignee: TOMITA PHARMACEUTICAL CO., LTD.
    Inventors: Sadayoshi Watanabe, Yukinori Konishi, Shota Minami, Akihito Bando, Naoyuki Kitamura
  • Patent number: 10532231
    Abstract: Natural haircare ingredient composition and haircare compositions containing such natural haircare ingredient compositions are provided. In one novel aspect, the natural hair ingredient composition is provided which comprises candida Krusei mediated bio-modification of marine organism and plants including bio-modified natural marine surfactants, three-dimensional molecular framework, and natural mineral salts. In one embodiment, the natural surfactants are produced from natural marine organisms such as brown algae, sea kelp, sponge, brown seaweeds, and red seaweeds by candida Krusei mediated bio-modification. In another novel aspect, a haircare composition comprises about 10% of the natural haircare ingredient composition, by weight of the haircare composition. In one novel aspect, Candida Krusei bio-modification process is used. Natural polymeric compounds in the marine plants are modified during the process resulting in three-dimensional molecular framework.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: January 14, 2020
    Assignee: Draco Natural Products Inc.
    Inventors: Jerry Wu, James-Jianguo Chen, Dong Li
  • Patent number: 10525011
    Abstract: A dosage form article consisting of a hard capsule coated with a surface modifying coating wherein the coating is an aqueous composition comprising water and a muco-adhesive polymer selected from the group consisting of poly(acrylates), cellulose derivatives, hyaluronic acid, starch, poly(ethylene glycol), polysaccharides, collagen derivatives, and mixtures thereof, wherein the ratio of the muco-adhesive polymer to water is less than 0.15 by weight of the coating composition.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: January 7, 2020
    Assignee: Capsugel Belgium NV
    Inventors: Dominique Nicolas Cade, Hugues Straub
  • Patent number: 10525079
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating breast cancer which includes tetraarsenic hexoxide in which a crystalline polymorph a(As4O6-a), of tetraarsenic hexoxide is 99% or higher, and to a method for producing the same. The composition of the present invention exhibits excellent effects of inhibiting the proliferation and metastasis of cancer cells, and thus can be usefully used as an anticancer agent.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: January 7, 2020
    Assignee: CHEMAS CO., LTD.
    Inventors: Ill Ju Bae, Zenglin Lian